Targeted Overexpression of Noncleavable and Secreted Forms of Tumor Necrosis Factor Provokes Disparate Cardiac Phenotypes
暂无分享,去创建一个
D. Mann | N. Sivasubramanian | B. Carabello | S. Nemoto | F. Spinale | A. Diwan | G. Defreitas | Z. Dibbs | E. M. Wilson | Eric M. Wilson
[1] Douglas L Mann,et al. Stress-activated cytokines and the heart: from adaptation to maladaptation. , 2003, Annual review of physiology.
[2] D. Mann,et al. Targeted Overexpression of Transmembrane Tumor Necrosis Factor Provokes a Concentric Cardiac Hypertrophic Phenotype , 2003, Circulation.
[3] Douglas L Mann,et al. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.
[4] D. Mann,et al. Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. , 2002, American journal of physiology. Heart and circulatory physiology.
[5] A. Feldman,et al. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. , 2002, American journal of physiology. Heart and circulatory physiology.
[6] D. Mann,et al. Left Ventricular Remodeling in Transgenic Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor , 2001, Circulation.
[7] Simon C Watkins,et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[8] M. Zile,et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. , 2000, Journal of molecular and cellular cardiology.
[9] M. Zile,et al. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. , 1999, The Journal of pharmacology and experimental therapeutics.
[10] M. Zile,et al. Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. , 1999, Circulation research.
[11] M. Satoh,et al. Tumor Necrosis Factor-α–Converting Enzyme and Tumor Necrosis Factor-α in Human Dilated Cardiomyopathy , 1999 .
[12] M. Satoh,et al. Tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human dilated cardiomyopathy. , 1999, Circulation.
[13] W. Abraham,et al. New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material. , 1998, Journal of cardiac failure.
[14] F. Clubb,et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.
[15] Nicole Nelson,et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.
[16] George Kollias,et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.